More recently, the introduction of anti-TNFα agents (e.g. adalimumab, etanercept) or the use of anti-CD20 B cell targeted therapy (rituximab, RTX) have provided a marked improvement in RA even if some patients do not respond or fail to maintain adequate response to these treatments [10], [11]. The gene discussed is TNF; the disease is rheumatoid arthritis.